Roche's Japanese arm gets green light for new arthritis drug trial
Chugai has been given the go-ahead to start clinical trials of its new arthritis treatment in Japan
Chugai has been given the go-ahead to start clinical trials of its new arthritis treatment in Japan.
The Japanese subsidiary of Roche has confirmed that regulators in the country have given the official green light to a new version of its Actemra arthritis treatment.
At first, Chugai launched the intravenous treatment on the Asian market in order to help treat Castleman's disease.
However, on the back of ongoing research, its scientists discovered that it could be tweaked to help treat inflammation caused by rheumatoid arthritis, with Japanese health regulators having now given the new drug formulation their go-ahead.
According to Reuters, Roche has also just submitted the new drug formulation to regulators in the United States, though no timeframe for a decision being made has been confirmed.
This comes soon after the pharmaceutical company announced plans to make more of the data obtained through its frequent clinical trials available to members of the scientific research community.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.